Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Madmax9on Jul 07, 2019 11:43am

128 Views

Post# 29893357

RE:Attention all dummies and shorters!!!

I think your right on that even at 12 to 1 that would not bring the price up high enough to make the difference to go to the level. If the results on the gvhd are as good as they sound then the fda will fast track them and then there will be a bidding war by big pharma and big players in cbd and thats all good for us. The dilution sucked the fact that share holders paid for the trials does not sit well but what's done is done. Till then just sit back and enjoy the summer glta!

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects